Cancer stem cells: The potential of carbon ion beam radiation and new radiosensitizers (Review)

Oncology Reports
Sung-Jae BaekKazuhiko Ogawa

Abstract

Cancer stem cells (CSCs) are a small population of cells in cancer with stem-like properties such as cell proliferation, multiple differentiation and tumor initiation capacities. CSCs are therapy-resistant and cause cancer metastasis and recurrence. One key issue in cancer therapy is how to target and eliminate CSCs, in order to cure cancer completely without relapse and metastasis. To target CSCs, many cell surface markers, DNAs and microRNAs are considered as CSC markers. To date, the majority of the reported markers are not very specific to CSCs and are also present in non-CSCs. However, the combination of several markers is quite valuable for identifying and targeting CSCs, although more specific identification methods are needed. While CSCs are considered as critical therapeutic targets, useful treatment methods remain to be established. Epigenetic gene regulators, microRNAs, are associated with tumor initiation and progression. MicroRNAs have been recently considered as promising therapeutic targets, which can alter the therapeutic resistance of CSCs through epigenetic modification. Moreover, carbon ion beam radiotherapy is a promising treatment for CSCs. Evidence indicates that the carbon ion beam is more effective again...Continue Reading

References

Oct 1, 1990·American Journal of Surgery·T R Loree, E W Strong
Nov 30, 1999·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B J BarrowR E Pollock
Nov 10, 2000·International Journal of Radiation Oncology, Biology, Physics·K M AlektiarM F Brennan
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·N UchidaI L Weissman
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Jul 28, 2004·International Journal of Radiation Oncology, Biology, Physics·Hirotoshi KatoUNKNOWN Liver Cancer Working Group
Mar 16, 2005·Cell·Steven M JohnsonFrank J Slack
Jun 10, 2005·Nature·Lin HeScott M Hammond
Jun 10, 2005·Nature·Kathryn A O'DonnellJoshua T Mendell
Jun 21, 2005·Nature Reviews. Cancer·John J Kim, Ian F Tannock
Apr 13, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takashi NakanoHirohiko Tsujii
Apr 22, 2006·International Journal of Radiation Oncology, Biology, Physics·Shingo KatoUNKNOWN Working Group of the Gynecological Tumor
Jun 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tetsuhiro ChibaHideki Taniguchi
Nov 7, 2006·International Journal of Radiation Oncology, Biology, Physics·Ed R BlazekGuitta Maki
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Nov 24, 2006·Nature·Lucia Ricci-VitianiRuggero De Maria
Dec 21, 2006·Journal of the National Cancer Institute·Tiffany M PhillipsFrank Pajonk
Jun 6, 2007·Cancer Cell International·Jayesh SagarAlexander Seifalian
Oct 3, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tadaaki MiyamotoUNKNOWN Working Group for Lung Cancer
Oct 13, 2007·Annals of Surgical Oncology·Keisuke IetaMasaki Mori
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anastasia MuratMonika E Hegi
Aug 21, 2008·International Journal of Cancer. Journal International Du Cancer·Sabine RiethdorfKlaus Pantel
Jul 9, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Junfang JiXin Wei Wang
Oct 2, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alberto FusiUlrich Keilholz
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marilena V Iorio, Carlo M Croce
Dec 2, 2009·Nature Reviews. Clinical Oncology·Marco Durante, Jay S Loeffler
Mar 12, 2010·Seminars in Cancer Biology·Ulrike KochMichael Baumann
Jul 13, 2011·International Journal of Radiation Oncology, Biology, Physics·Keiichi JinguUNKNOWN Organizing Committee for the Working Group for Head-and-Neck Cancer
Feb 11, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Hitoshi IshikawaUNKNOWN Working Group for Genitourinary Tumors

❮ Previous
Next ❯

Citations

Jul 15, 2020·Cells·María Auxiliadora Olivares-UrbanoMaría Isabel Núñez
Oct 26, 2016·Oncology Reports·Sung-Jae BaekKazuhiko Ogawa
Oct 22, 2020·Cancers·Walter Tinganelli, Marco Durante
Dec 20, 2020·International Journal of Molecular Sciences·Walter Tinganelli, Marco Durante

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.